The Study, which is a Phase IIa trial, will be conducted under the leadership of principal investigator, Andrea Branch, PhD, Professor of Medicine in the Icahn School of
KYNAMRO is approved in the United States for use in patients with homozygous familial hypercholesterolemia (HoFH) to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC)
This is the first company sponsored clinical trial evaluating the safety, tolerability, and efficacy of TG-1101 in autoimmune diseases. The Company is also supporting an investigator-sponsored study at
Papulopustular rosacea is a chronic skin disorder characterized by facial redness and inflammatory lesions. It affects more than 16 million people in the U.S. alone. The most common
As per the agreement, Ionis will receive up to $95m and will earn royalties on global sales of Kynamro starting in 2017. Ionis will also receive a 10%
The complainant is a 62-year-old American woman named Gloria Ristesund. She said that she had used J&J’s talc-based powder products, which include the Baby Powder and Shower to
Deerfield Management Company led the series B financing round, which included participation from OrbiMed Advisors, Clarus Ventures, and Hatteras Venture Partners. Graybug will use the proceeds to further
Fycompa is already available in 43 countries in 2 mg, 4 mg, 6 mg, and 8 mg, 10 mg, and 12 mg tablets. The updated formulation is now
TAF is a novel targeted prodrug of tenofovir that has showed high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread (tenofovir
The European Commission delivers its final decision within three months. It will be applicable to all 28 European Union member states and Iceland as well as Norway. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.